ATE545033T1 - Diagnostische verfahren für hiv-infektion - Google Patents

Diagnostische verfahren für hiv-infektion

Info

Publication number
ATE545033T1
ATE545033T1 AT08806601T AT08806601T ATE545033T1 AT E545033 T1 ATE545033 T1 AT E545033T1 AT 08806601 T AT08806601 T AT 08806601T AT 08806601 T AT08806601 T AT 08806601T AT E545033 T1 ATE545033 T1 AT E545033T1
Authority
AT
Austria
Prior art keywords
inhibiting
viral infection
polypeptide
expression
provides
Prior art date
Application number
AT08806601T
Other languages
English (en)
Inventor
Annapurna Vyakarnam
David Rowley
Steven Ressler
Original Assignee
King S College London
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London, Baylor College Medicine filed Critical King S College London
Application granted granted Critical
Publication of ATE545033T1 publication Critical patent/ATE545033T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
AT08806601T 2007-10-15 2008-10-15 Diagnostische verfahren für hiv-infektion ATE545033T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99895307P 2007-10-15 2007-10-15
US99895107P 2007-10-15 2007-10-15
PCT/GB2008/003477 WO2009050444A1 (en) 2007-10-15 2008-10-15 Diagnostic methods for hiv infection

Publications (1)

Publication Number Publication Date
ATE545033T1 true ATE545033T1 (de) 2012-02-15

Family

ID=40351503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08806601T ATE545033T1 (de) 2007-10-15 2008-10-15 Diagnostische verfahren für hiv-infektion

Country Status (4)

Country Link
US (2) US20100216119A1 (de)
EP (2) EP2209810A1 (de)
AT (1) ATE545033T1 (de)
WO (2) WO2009050446A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
EP3201227A4 (de) 2014-09-29 2018-04-18 Duke University Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
EP1400536A1 (de) * 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
EP1291360A1 (de) * 1991-12-13 2003-03-12 Xoma Corporation Verfahren und Materialien zur Herstellung von modifizierten Antikörper Variablen Domänen und deren therapeutischen Verwendung
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
JP2000501603A (ja) * 1995-12-07 2000-02-15 ベイラー・カレッジ・オブ・メディスン 尿生殖洞由来増殖因子のヌクレオチドおよびアミノ酸配列
AU2006304382A1 (en) * 2005-10-14 2007-04-26 The Johns Hopkins School Of Medicine Reduction and prevention of cell-associated HIV transepithelial migration, microbides and other formulations and methods

Also Published As

Publication number Publication date
EP2209810A1 (de) 2010-07-28
EP2210112B1 (de) 2012-02-08
US20110212076A1 (en) 2011-09-01
WO2009050446A1 (en) 2009-04-23
US20100216119A1 (en) 2010-08-26
WO2009050444A1 (en) 2009-04-23
EP2210112A1 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
ATE545033T1 (de) Diagnostische verfahren für hiv-infektion
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
RU2017146409A (ru) Способы прогнозирования рака предстательной железы
IN2014CN03508A (de)
WO2008021290A8 (en) Organ-specific proteins and methods of their use
IL192866A (en) Detecting cancer with high levels of 2 bcl
EP2569635A4 (de) Verfahren zur diagnose und/oder behandlung von enzephalitis oder epilepsie
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PH12012502065A1 (en) Methods for measuring enzyme activity useful in determining cell viability in non-purified samples
WO2010033597A3 (en) Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
MX356623B (es) Equipo para muestreo y deteccion de endotoxina en solucion acuosa.
MX371379B (es) Deteccion de la actividad de corte de una enzima.
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
NZ593392A (en) Biomarker for detecting bladder cancer
MX2007009547A (es) Metodo de deteccion de fiebre porcina clasica.
MY163078A (en) Rapid and accurate analysis of protein sialylation
ATE447182T1 (de) Verfahren zur zellerkennung sowie verwendung eines wirkstoffs zum durchbrechen einer wasserstoffbindung
ATE549417T1 (de) Diagnoseverfahren für osteoarthritis
WO2014011416A3 (en) Cell-based assay for neutralizing antibodies
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
WO2012097207A3 (en) Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome